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Purpose. To assess an eﬀect of glycemic control on retinal nerve ﬁber layer (RNFL) in type 2 diabetes mellitus. Methods. Thirty-
eight eyes of 38 patients with type 2 diabetes undergoing blood glucose regulation were enrolled. All patients were examined at (1)
initial visit, (2) 1 month, (3) 2 months, and (4) 4-month after the initial examination. On each occasion, glycosylated hemoglobin
(HbA1c) levels and optical coherence tomography (OCT) scanning for RNFL thickness were evaluated. 360 degree circular OCT
scans with a diameter of 3.4mm centered on the optic disc were performed. Results. Signiﬁcant RNFL decrease was seen in the
superior area between initial and 4 months examination (P = .043). The relationship between the changes in HbA1c and the
changes in RNFL thickness was observed in superior, temporal, and inferior area (P<. 05) at 4 months. Conclusions. This study
suggests that the glycemic control aﬀects RNFL within 4 months.
1.Introduction
Diabetes mellitus (DM) is a chronic illness and diabetic
retinopathy (DR) is a main cause of blindness in working age
[1]. Large randomized-clinical trials suggest that intensive
management of hyperglycemia is associated with decreased
rates of development and progression of DR in type 1 DM
patients [2] and that glycemic control in type 2 DM patients
resulted in a 25% risk reduction in retinal microvascular
events [3]. Thus, excess glucose is generally considered to be
the primary culprit in the progression of DR, and glycemic
control can prevent this. But contrary, intensive glycemic
control sometimes causes worsening of DR [4]. Glycemic
control may have a negative eﬀect on the retina, even though
longitude control works well. Not much has been done to
clarify what occurs in the retina during glycemic control [5–
7], so further studies are needed to elucidate this question.
In glaucoma eyes, retinal nerve ﬁber layer (RNFL)
decreasesasaprogression[8]andmanystudiesalsoreported
RNFL changes in DM patients [9–14], but to our knowledge,
only a few studies have evaluated the relationship between
RNFL thickness and glycemic control [15]. These days,
various instruments have been established for evaluation
of RNFL with no invasion. Especially, optical coherence
tomography (OCT) has been proposed as a powerful tool
for retinal measurement and provides detailed information
with a high resolution [16–18]. OCT can also evaluate RNFL
thickness with a high reliability [19]. We hypothesize that
RNFL thickness is aﬀected by glycemic control and indicates
retinal damage. Here, we conducted a study to assess the
eﬀect of glycemic control on RNFL thickness using this
useful OCT and to identify what occurs in the retina during
glycemic control.
2.SubjectsandMethods
2.1. Subjects. Patients with type 2 DM who had been
referred to our endocrinology department for blood glucose
regulation were assessed for the study. All patients were
Japanese and one eye of each subject was selected randomly
for examination. Informed consent was obtained from each
of the participants. All subjects were treated in accordance
with the declaration of Helsinki for Clinical Research and
the study was conducted with the understanding and the2 Journal of Ophthalmology
consent of the human subject. They were receiving treatment
with diet and exercise, oral hypoglycemic agents, or insulin.
All subjects were examined as follows: (1) initial visit, (2)
1 month, (3) 2 months, and (4) 4 months after the initial
examination. On each occasion, glycosylated hemoglobin
(HbA1c) levels and general ophthalmic evaluations includ-
ing OCT scanning were examined. Fundus examination and
OCT scanning were done under dilated condition using
1% tropicamide and 2.5% phenylephrine hydrochloride.
Patients underwent fundus examination using a +90 diopter
lens and were classiﬁed by an independent grader according
to the criteria of the ETDRS protocol [20]. The progression
of DR was deﬁned as the examination of retinal signs from
this classiﬁcation.
Eligible subjects had to meet the following criteria: (1)
subjects whose HbA1c on initial examination was over 7.0,
(2) subjects who could be followed up over 4 months, and
(3) improved glycemic control evaluated using HbA1c was
satisfactorily achieved. A reduction of HbA1c after 4 months
by 10% or more was deﬁned as an improvement. HbA1c
was measured each time at our hospital in order to provide
uniformity among laboratory results.
Eyes with high myopia, neural ophthalmic anomalies,
advanced cataract, cloudy media, and intraocular pressure
over 21mmHg as determined by Goldmann applanation
tonometry were excluded from the evaluation. They had no
other history of other eye disease, surgery, and photoco-
agulation. All subjects had normal optic disc appearance.
Normal optic disc appearance was deﬁned as a vertical
asymmetry of 0.2 or less, a cup-disc ratio of 0.6 or
less, and an intact neuroretinal rim without peripapillary
hemorrhages, notches, localized pallor, or RNFL defect on
clinical examination. Those eyes with progression of DR
which required photocoagulation or other therapy during
follow-up terms were excluded and therapies were initiated.
2.2. OCT Scanning and Analysis. OCT (OCT 1, Zeiss-
Humphrey Systems, Dublin, CA) scanning was performed
using near-infrared, low-coherence illumination (840nm)
with a tissue resolution of approximately 10–17μm[ 15–
18]. At each setting, two or three OCT scans were acquired
for each patient. From the acquired scans, the best quality,
properly aligned scan was chosen for analysis. One trained
ophthalmologists (MS) performed all of the procedures.
The 360◦ circular scans with a diameter of 3.4mm
centered on the optic disc were performed as previously
described [21, 22]. The scans were centered on the optic
disc while patients looked upon landmark points. Fixation
was monitored and controlled by the video image of the
centralopticdisc.RNFLthicknesswasdeﬁnedasthenumber
of pixels between the anterior and posterior edge of the
RNFL detected using the attached automatic boundary
detection software (version A5, Humphrey-Zeiss). Each
resulting image consists of RNFL thickness measurements at
100 points along a 360◦ circular ring around the optic disc.
RNFL thickness was calculated automatically with existing
software: mean (all 360◦ measurements), temporal quadrant
(316◦–45◦ unit circle), superior quadrant (46◦–135◦), nasal
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Figure 1: Schematic image of OCT scanning for retinal nerve ﬁber
layer (RNFL) thickness measurements. The circle shows a 360◦
circular scan with 3.4mm diameter. Two lines divide the circle into
4 quadrants (temporal, superior, nasal, inferior).
Table 1: Change in HbA1c during glycemic control.
HbA1c (%)
Initial 9.20 ± 1.53
1M 8.43 ± 1.32∗
2M 7.44 ± 1.28∗
4M 7.35 ± 1.29∗
The HbA1c is expressed in mean ± standard deviations.
∗Statistically signiﬁcant values at P<. 05.
quadrant (136◦–225◦) and inferior quadrant (226◦–315◦)
thickness (Figure 1).
2.3. Statistical Analysis. Results were shown as the mean val-
ues ± standard deviations. Statistical analysis was performed
using JMP5.01J (SAS Institute Inc, Cary, NC). Signiﬁcant
diﬀerences were determined by use of a non-repeated
measures analysis of variance (ANOVA) and SNK test as
a post hoc test. Pearson correlation analysis was used for
correlation according to a linear regression analysis model.
The student’s t-test for paired group was used for analysis. A
P value of <.05 was considered statistically signiﬁcant.
3. Results
We identiﬁed 38 eyes of 38 patients as meeting the criteria
for study. Mean age was 60.5 ± 9.05 (yrs). Eight patients
were placed on only diet and exercise therapy, 20 patients
were treated with oral hypoglycemic agents alone, and 10
patients were treated with insulin alone. Twenty-four eyes
had no retinopathy and 14 eyes had nonproliferative diabetic
retinopathy.Duringthestudy,noeyesshowedprogressionof
retinopathy for advanced treatments.
AsigniﬁcantdecreaseofHbA1cwasseen,whichindicates
fair glycemic control (P = .00233, non-repeated measures of
ANOVA, Table 1).Journal of Ophthalmology 3
Table 2: Change in retinal nerve ﬁber layer thickness during glycemic control.
Mean Temporal Superior Nasal Inferior
Initial 127.2 ± 13.8 111.2 ± 16.8 145.7 ± 17.3 110.2 ± 15.8 142.2 ± 17.9
1M 126.0 ± 12.3 109.4 ± 18.0 143.7 ± 16.8 110.2 ± 17.0 141.3 ± 16.3
2M 126.7 ± 12.1 111.8 ± 17.5 143.2 ± 18.1 108.8 ± 14.9 143.4 ± 15.0
4M 124.4 ± 12.7 109.5 ± 18.9 139.9 ± 14.6∗ 106.8 ± 17.1 141.7 ± 16.9
(μm)
RNFL thickness is expressed in mean ± standard deviations.
∗Statistically signiﬁcant values at P<. 05.
During OCT analysis in all quadrant areas, no sig-
niﬁcant RNFL change was seen between the initial and
1 or 2 month examination. But a signiﬁcant decrease
was seen in the superior area between the initial and 4
month examination (P = .043, non-repeated measures of
ANOVA, Table 2). No signiﬁcant change was found in other
areas.
Next, to clarify the relationship between the change
in HbA1c (dHbA1c) and the changes in RNFL thickness
(dRNFLT)after4monthsofcontrol,wecomparethemusing
Pearson correlation analysis. The dRNFLT was related to the
dHbA1c in the superior, temporal, and inferior quadrants
(P<. 05 in each area, student’s t-test, Figure 2). No
correlation was seen in the nasal quadrant.
4. Discussion
In this study, RNFL thickness decreased in all quadrants area
after 4 months of glycemic control. Especially, signiﬁcant
decrease was seen in the superior area. Generally, in glau-
comatous eyes, the RNFL is initially damaged in superior
area [23–26] and previously we reported that superior
RNFL thickness is already decreased in the early stage of
DR [22]. Additionally, in vivo study using diabetic animal
showed that there were more micro aneurysms seen in
superior than in inferior area [27] .S ot h i sa r e ai sm o r e
susceptible to damage than other areas and may have a
tendency for higher rates of cell death, which results in
RNFL thinning. There remains a question that thinning
of the RNFL does not necessarily mean a loss of retinal
n e r v eﬁ b e r sa n dt h eR N F Lm a yh a v eb e e ns w o l l e nd u et oa
partial blockade of the axoplasmic ﬂow in the hyperglycemic
state. But our data indicates some kind of change, including
thinning, occuring in retina components. Thus, superior
RNFL thickness is an indicator for retinal damage under the
glycemic control.
According to clinical evidence, there is no doubt that
glycemic control is most important for stability of DM
and DR. But intensive glycemic control sometimes induces
worsening of DR, known as an early worsening (EW)
[28]. As the worsening results, hard exudates and macular
edema occur. Intensive glycemic control may lead to a
transient deterioration of DR and patients who already have
background DR are at higher risk for EW changes [29]. On
this point, Funatsu et al. emphasized that a 2% or more
decrease in HbA1c accelerate DR progression [30]. It should
be noted that several reports also have shown interaction
betweenglycemiccontrolandretinachangeincludingblood-
retina barrier (BRB) or macula edema progression [5–7].
Suchvascularbreakdownmaychangethetissueconstruction
and it is reasonable to propose that RNFL damage is
followed by this change as an aspect of neurodegeneric
change. Some molecular mechanism may participate in this
change and some experimental studies have shown that
insulin stimulates a cascade of neovascularization. Vascular
endothelialgrowthfactor(VEGF)[31,32]isoneofthemajor
mediators of neovascularization or ischemia. Insulin up-
regulates VEGF in vitro and enhances vascular permeability
or proliferative eﬀects [33, 34] which results in proliferative
retinal changes. Thus, insulin itself plays an important
role in neovascularization or BRB breakdown and may be
one of the causes of several complications during glycemic
control, including EW. Patients in this study were treated
variably; some were given insulin, some were given oral
agent, and some were treated without medication. Because
of the small number of patients, there was no signiﬁcant
RNFLthicknesschangeforourtenofinsulin-treatedpatients
and other patients in each area between the initial visit
and each subsequent visit (P>. 05 in each area, data not
shown). And there is a report that progression of DR diﬀers
by insulin type [35], so further clariﬁcation is needed to
examine the relation between RNFL damage and insulin.
This is a pilot study which gives support to further studies
in these areas. Having had more sample number would
have been helpful in truly allowing the hypothesis that
the correlation between HbA1c levels and RNFL thinning
is due to insulin or other factors. And in addition, there
exists several problems in our study. First, the patients are
poorly characterized in aspects of several factors such as
age, sex, duration of diabetes, coexistent renal disease and
blood pressure (BP). As several studies mentioned about
importance of BP control for prevention of DR [36], it
is important to consider BP control. There is a possibility
that increased BP and secondary increase in cerebrospinal
ﬂuid pressure may relate with RNFL change. Second, we
did not use updated technology of OCT which can detect
much detailed change than OCT 1, which we used here.
And third, there is a possibility that visual ﬁelds evaluation
may support our results much precisely. On these points,
we need much larger and suﬃciently-powered follow-up
study.4 Journal of Ophthalmology
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Figure 2: The relationship between HbA1c changes (dHbA1c) and RNFL thickness changes (dRNFLT) in (a) Temporal, (b) Superior,
(c) Nasal, (d) Inferior quadrant area. The lines are from a linear regression analysis. There is a signiﬁcant correlation in temporal
(P = .0001), superior (P = .013) and inferior quadrant area (P = .005). There is no signiﬁcant correlation in nasal quadrant
area.
5. Conclusion
In summary, this study suggests that the glycemic control
aﬀects RNFL within 4 months and superior RNFL thickness
can be used as an indicator for this change. Moreover, it may
provide further new information regarding the mechanism
of EW.
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